Baidu
map

Oncogene:拮抗剂贝沙罗汀靶向TR4核受体能够增加前列腺癌对多烯紫杉醇的敏感性

2019-12-04 AlexYang MedSci原创

前列腺癌(PCa)是美国男性癌症死亡的第二大原因,并且转移去势抵抗性前列腺癌(mCRPC)患者没有治疗选择。多烯紫杉醇(DTX)是mCRPC的一种标准的化疗疗法。然而,对DTX的抗性是一个明显的临床问题,并且导致了半数患者对治疗没有响应。TR4核受体被报道在PCa恶化过程中具有重要的作用,然而,它与DTX抗性之间的关系仍旧未知。最近,有研究人员发现TR4在DTX化疗之后的mCRPC细胞和患者中表达

前列腺癌(PCa)是美国男性癌症死亡的第二大原因,并且转移去势抵抗性前列腺癌(mCRPC)患者没有治疗选择。多烯紫杉醇(DTX)是mCRPC的一种标准的化疗疗法。然而,对DTX的抗性是一个明显的临床问题,并且导致了半数患者对治疗没有响应。TR4核受体被报道在PCa恶化过程中具有重要的作用,然而,它与DTX抗性之间的关系仍旧未知。

最近,有研究人员发现TR4在DTX化疗之后的mCRPC细胞和患者中表达上调,并且TR4的表达与DTX的敏感性相关,且具有较高的耐药水平。使用拮抗剂贝沙罗汀靶向TR4能够抑制TR4的反式激活并增加DTX的化疗抗性。机制解析研究阐释了TR4可能能够通过协调TR4/lincRNA-p21/HIF-1α/VEGF-A信号来改变DTX化疗抗性。

最后,研究人员指出,他们的结果表明了通过贝沙罗汀(Bex)靶向TR4/lincRNA-p21/HIF-1α/VEGF-A信号途径,也许能够增加DTX的化疗敏感性,从而更好的抑制mCRPC的恶化。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2086095, encodeId=afa42086095f0, content=<a href='/topic/show?id=d8c49222ef0' target=_blank style='color:#2F92EE;'>#贝沙罗汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92227, encryptionId=d8c49222ef0, topicName=贝沙罗汀)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c982214, createdName=tomyang86, createdTime=Wed Dec 18 10:00:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677277, encodeId=caa316e727759, content=<a href='/topic/show?id=6e7462063f0' target=_blank style='color:#2F92EE;'>#核受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62063, encryptionId=6e7462063f0, topicName=核受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24727466716, createdName=ysjykql, createdTime=Tue Sep 08 02:00:00 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770511, encodeId=8cd21e705112b, content=<a href='/topic/show?id=05fe2665508' target=_blank style='color:#2F92EE;'>#体能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26655, encryptionId=05fe2665508, topicName=体能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ae38174281, createdName=liubm568, createdTime=Tue Nov 03 01:00:00 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049257, encodeId=e1e7204925ec3, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Feb 06 20:00:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388475, encodeId=83f413884e580, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417361, encodeId=a80d141e361b1, content=<a href='/topic/show?id=28ca43332b5' target=_blank style='color:#2F92EE;'>#多烯紫杉醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43332, encryptionId=28ca43332b5, topicName=多烯紫杉醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63eb3265522, createdName=zhangmingxiang, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511746, encodeId=4fbb1511e4610, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558175, encodeId=931815581e5cb, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040611, encodeId=fe3a104061189, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Dec 04 16:00:00 CST 2019, time=2019-12-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2086095, encodeId=afa42086095f0, content=<a href='/topic/show?id=d8c49222ef0' target=_blank style='color:#2F92EE;'>#贝沙罗汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92227, encryptionId=d8c49222ef0, topicName=贝沙罗汀)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c982214, createdName=tomyang86, createdTime=Wed Dec 18 10:00:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677277, encodeId=caa316e727759, content=<a href='/topic/show?id=6e7462063f0' target=_blank style='color:#2F92EE;'>#核受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62063, encryptionId=6e7462063f0, topicName=核受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24727466716, createdName=ysjykql, createdTime=Tue Sep 08 02:00:00 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770511, encodeId=8cd21e705112b, content=<a href='/topic/show?id=05fe2665508' target=_blank style='color:#2F92EE;'>#体能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26655, encryptionId=05fe2665508, topicName=体能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ae38174281, createdName=liubm568, createdTime=Tue Nov 03 01:00:00 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049257, encodeId=e1e7204925ec3, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Feb 06 20:00:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388475, encodeId=83f413884e580, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417361, encodeId=a80d141e361b1, content=<a href='/topic/show?id=28ca43332b5' target=_blank style='color:#2F92EE;'>#多烯紫杉醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43332, encryptionId=28ca43332b5, topicName=多烯紫杉醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63eb3265522, createdName=zhangmingxiang, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511746, encodeId=4fbb1511e4610, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558175, encodeId=931815581e5cb, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040611, encodeId=fe3a104061189, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Dec 04 16:00:00 CST 2019, time=2019-12-04, status=1, ipAttribution=)]
    2020-09-08 ysjykql
  3. [GetPortalCommentsPageByObjectIdResponse(id=2086095, encodeId=afa42086095f0, content=<a href='/topic/show?id=d8c49222ef0' target=_blank style='color:#2F92EE;'>#贝沙罗汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92227, encryptionId=d8c49222ef0, topicName=贝沙罗汀)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c982214, createdName=tomyang86, createdTime=Wed Dec 18 10:00:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677277, encodeId=caa316e727759, content=<a href='/topic/show?id=6e7462063f0' target=_blank style='color:#2F92EE;'>#核受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62063, encryptionId=6e7462063f0, topicName=核受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24727466716, createdName=ysjykql, createdTime=Tue Sep 08 02:00:00 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770511, encodeId=8cd21e705112b, content=<a href='/topic/show?id=05fe2665508' target=_blank style='color:#2F92EE;'>#体能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26655, encryptionId=05fe2665508, topicName=体能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ae38174281, createdName=liubm568, createdTime=Tue Nov 03 01:00:00 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049257, encodeId=e1e7204925ec3, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Feb 06 20:00:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388475, encodeId=83f413884e580, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417361, encodeId=a80d141e361b1, content=<a href='/topic/show?id=28ca43332b5' target=_blank style='color:#2F92EE;'>#多烯紫杉醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43332, encryptionId=28ca43332b5, topicName=多烯紫杉醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63eb3265522, createdName=zhangmingxiang, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511746, encodeId=4fbb1511e4610, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558175, encodeId=931815581e5cb, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040611, encodeId=fe3a104061189, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Dec 04 16:00:00 CST 2019, time=2019-12-04, status=1, ipAttribution=)]
    2020-11-03 liubm568
  4. [GetPortalCommentsPageByObjectIdResponse(id=2086095, encodeId=afa42086095f0, content=<a href='/topic/show?id=d8c49222ef0' target=_blank style='color:#2F92EE;'>#贝沙罗汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92227, encryptionId=d8c49222ef0, topicName=贝沙罗汀)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c982214, createdName=tomyang86, createdTime=Wed Dec 18 10:00:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677277, encodeId=caa316e727759, content=<a href='/topic/show?id=6e7462063f0' target=_blank style='color:#2F92EE;'>#核受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62063, encryptionId=6e7462063f0, topicName=核受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24727466716, createdName=ysjykql, createdTime=Tue Sep 08 02:00:00 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770511, encodeId=8cd21e705112b, content=<a href='/topic/show?id=05fe2665508' target=_blank style='color:#2F92EE;'>#体能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26655, encryptionId=05fe2665508, topicName=体能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ae38174281, createdName=liubm568, createdTime=Tue Nov 03 01:00:00 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049257, encodeId=e1e7204925ec3, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Feb 06 20:00:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388475, encodeId=83f413884e580, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417361, encodeId=a80d141e361b1, content=<a href='/topic/show?id=28ca43332b5' target=_blank style='color:#2F92EE;'>#多烯紫杉醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43332, encryptionId=28ca43332b5, topicName=多烯紫杉醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63eb3265522, createdName=zhangmingxiang, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511746, encodeId=4fbb1511e4610, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558175, encodeId=931815581e5cb, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040611, encodeId=fe3a104061189, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Dec 04 16:00:00 CST 2019, time=2019-12-04, status=1, ipAttribution=)]
    2020-02-06 cy0324
  5. [GetPortalCommentsPageByObjectIdResponse(id=2086095, encodeId=afa42086095f0, content=<a href='/topic/show?id=d8c49222ef0' target=_blank style='color:#2F92EE;'>#贝沙罗汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92227, encryptionId=d8c49222ef0, topicName=贝沙罗汀)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c982214, createdName=tomyang86, createdTime=Wed Dec 18 10:00:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677277, encodeId=caa316e727759, content=<a href='/topic/show?id=6e7462063f0' target=_blank style='color:#2F92EE;'>#核受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62063, encryptionId=6e7462063f0, topicName=核受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24727466716, createdName=ysjykql, createdTime=Tue Sep 08 02:00:00 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770511, encodeId=8cd21e705112b, content=<a href='/topic/show?id=05fe2665508' target=_blank style='color:#2F92EE;'>#体能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26655, encryptionId=05fe2665508, topicName=体能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ae38174281, createdName=liubm568, createdTime=Tue Nov 03 01:00:00 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049257, encodeId=e1e7204925ec3, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Feb 06 20:00:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388475, encodeId=83f413884e580, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417361, encodeId=a80d141e361b1, content=<a href='/topic/show?id=28ca43332b5' target=_blank style='color:#2F92EE;'>#多烯紫杉醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43332, encryptionId=28ca43332b5, topicName=多烯紫杉醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63eb3265522, createdName=zhangmingxiang, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511746, encodeId=4fbb1511e4610, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558175, encodeId=931815581e5cb, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040611, encodeId=fe3a104061189, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Dec 04 16:00:00 CST 2019, time=2019-12-04, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2086095, encodeId=afa42086095f0, content=<a href='/topic/show?id=d8c49222ef0' target=_blank style='color:#2F92EE;'>#贝沙罗汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92227, encryptionId=d8c49222ef0, topicName=贝沙罗汀)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c982214, createdName=tomyang86, createdTime=Wed Dec 18 10:00:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677277, encodeId=caa316e727759, content=<a href='/topic/show?id=6e7462063f0' target=_blank style='color:#2F92EE;'>#核受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62063, encryptionId=6e7462063f0, topicName=核受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24727466716, createdName=ysjykql, createdTime=Tue Sep 08 02:00:00 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770511, encodeId=8cd21e705112b, content=<a href='/topic/show?id=05fe2665508' target=_blank style='color:#2F92EE;'>#体能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26655, encryptionId=05fe2665508, topicName=体能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ae38174281, createdName=liubm568, createdTime=Tue Nov 03 01:00:00 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049257, encodeId=e1e7204925ec3, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Feb 06 20:00:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388475, encodeId=83f413884e580, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417361, encodeId=a80d141e361b1, content=<a href='/topic/show?id=28ca43332b5' target=_blank style='color:#2F92EE;'>#多烯紫杉醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43332, encryptionId=28ca43332b5, topicName=多烯紫杉醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63eb3265522, createdName=zhangmingxiang, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511746, encodeId=4fbb1511e4610, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558175, encodeId=931815581e5cb, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040611, encodeId=fe3a104061189, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Dec 04 16:00:00 CST 2019, time=2019-12-04, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2086095, encodeId=afa42086095f0, content=<a href='/topic/show?id=d8c49222ef0' target=_blank style='color:#2F92EE;'>#贝沙罗汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92227, encryptionId=d8c49222ef0, topicName=贝沙罗汀)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c982214, createdName=tomyang86, createdTime=Wed Dec 18 10:00:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677277, encodeId=caa316e727759, content=<a href='/topic/show?id=6e7462063f0' target=_blank style='color:#2F92EE;'>#核受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62063, encryptionId=6e7462063f0, topicName=核受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24727466716, createdName=ysjykql, createdTime=Tue Sep 08 02:00:00 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770511, encodeId=8cd21e705112b, content=<a href='/topic/show?id=05fe2665508' target=_blank style='color:#2F92EE;'>#体能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26655, encryptionId=05fe2665508, topicName=体能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ae38174281, createdName=liubm568, createdTime=Tue Nov 03 01:00:00 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049257, encodeId=e1e7204925ec3, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Feb 06 20:00:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388475, encodeId=83f413884e580, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417361, encodeId=a80d141e361b1, content=<a href='/topic/show?id=28ca43332b5' target=_blank style='color:#2F92EE;'>#多烯紫杉醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43332, encryptionId=28ca43332b5, topicName=多烯紫杉醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63eb3265522, createdName=zhangmingxiang, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511746, encodeId=4fbb1511e4610, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558175, encodeId=931815581e5cb, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040611, encodeId=fe3a104061189, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Dec 04 16:00:00 CST 2019, time=2019-12-04, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2086095, encodeId=afa42086095f0, content=<a href='/topic/show?id=d8c49222ef0' target=_blank style='color:#2F92EE;'>#贝沙罗汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92227, encryptionId=d8c49222ef0, topicName=贝沙罗汀)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c982214, createdName=tomyang86, createdTime=Wed Dec 18 10:00:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677277, encodeId=caa316e727759, content=<a href='/topic/show?id=6e7462063f0' target=_blank style='color:#2F92EE;'>#核受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62063, encryptionId=6e7462063f0, topicName=核受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24727466716, createdName=ysjykql, createdTime=Tue Sep 08 02:00:00 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770511, encodeId=8cd21e705112b, content=<a href='/topic/show?id=05fe2665508' target=_blank style='color:#2F92EE;'>#体能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26655, encryptionId=05fe2665508, topicName=体能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ae38174281, createdName=liubm568, createdTime=Tue Nov 03 01:00:00 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049257, encodeId=e1e7204925ec3, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Feb 06 20:00:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388475, encodeId=83f413884e580, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417361, encodeId=a80d141e361b1, content=<a href='/topic/show?id=28ca43332b5' target=_blank style='color:#2F92EE;'>#多烯紫杉醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43332, encryptionId=28ca43332b5, topicName=多烯紫杉醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63eb3265522, createdName=zhangmingxiang, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511746, encodeId=4fbb1511e4610, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558175, encodeId=931815581e5cb, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040611, encodeId=fe3a104061189, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Dec 04 16:00:00 CST 2019, time=2019-12-04, status=1, ipAttribution=)]
    2019-12-06 zsyan
  9. [GetPortalCommentsPageByObjectIdResponse(id=2086095, encodeId=afa42086095f0, content=<a href='/topic/show?id=d8c49222ef0' target=_blank style='color:#2F92EE;'>#贝沙罗汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92227, encryptionId=d8c49222ef0, topicName=贝沙罗汀)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c982214, createdName=tomyang86, createdTime=Wed Dec 18 10:00:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677277, encodeId=caa316e727759, content=<a href='/topic/show?id=6e7462063f0' target=_blank style='color:#2F92EE;'>#核受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62063, encryptionId=6e7462063f0, topicName=核受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24727466716, createdName=ysjykql, createdTime=Tue Sep 08 02:00:00 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770511, encodeId=8cd21e705112b, content=<a href='/topic/show?id=05fe2665508' target=_blank style='color:#2F92EE;'>#体能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26655, encryptionId=05fe2665508, topicName=体能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ae38174281, createdName=liubm568, createdTime=Tue Nov 03 01:00:00 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049257, encodeId=e1e7204925ec3, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Feb 06 20:00:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388475, encodeId=83f413884e580, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417361, encodeId=a80d141e361b1, content=<a href='/topic/show?id=28ca43332b5' target=_blank style='color:#2F92EE;'>#多烯紫杉醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43332, encryptionId=28ca43332b5, topicName=多烯紫杉醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63eb3265522, createdName=zhangmingxiang, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511746, encodeId=4fbb1511e4610, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558175, encodeId=931815581e5cb, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Dec 06 04:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040611, encodeId=fe3a104061189, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Dec 04 16:00:00 CST 2019, time=2019-12-04, status=1, ipAttribution=)]
    2019-12-04 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Oncogene:BRF1能够促进前列腺致瘤和干扰免疫浸润

BRF1是RNA聚合酶III介导转录的限速因子,并在多种癌症中表达上调。最近,有研究人员报道了BRF1表达的提高与人类前列腺癌不良的预后相关。人类前列腺癌细胞系体外研究阐释了BRF1的瞬时过表达能够增加细胞增殖,而BRF1的瞬时下调能够减少细胞增殖和介导细胞周期阻滞。与临床观察一致的是,Pten缺陷小鼠前列腺癌模型(PtenΔ/Δ BRF1Tg)中,BRF1的过表达能够促进前列腺癌的发生和缩短生存

Brit J Cancer:转移去势抵抗性前列腺癌中卡巴他赛治疗的总生存和无进展生存研究

卡巴他赛是多烯紫杉醇治疗去势抵抗性前列腺癌(mCRPC)失败后的一种治疗方法。FUJI群体旨在确定卡巴他赛在现实生活中总生存(OS)、无进展生存(PFS)和安全性情况。研究是一个多中心、非介入性群体研究,时间为2013年到2015年,跟踪调查时间为18个月。研究包括了42个中心的401名患者。入选患者的平均年龄为70岁,主要转移位点为骨组织(87%)、淋巴结(42%)和内脏(18%)。18%的患者

Lancet Oncol:80% BRCA突变患者有反应!奥拉帕利治疗前列腺癌患者试验发表

PARP抑制剂奥拉帕利是首个在中国问世的卵巢癌靶向新药,在美国、欧盟、日本还已获批乳腺癌适应症,其跨多个癌种的应用潜力也备受业界关注,在研适应症还包括胰腺癌和前列腺癌等。

Prostate Cancer P D:水蒸气热疗能够减轻导管依赖的尿滞留

水蒸汽热疗通过利用对流传递的热能来靶向消融阻塞性前列腺组织。最近,有研究人员报道了该热疗方法在减轻与良性前列腺增生(BPH)相关的非神经性尿滞留上的结果情况。研究人员对38名导管依赖的男性进行了回顾性的分析,他们的平均年龄为75.5岁。研究发现,在治疗的38名患者中,1名患者在跟踪调查时丢失,剩下的37名中的26名(70.3%)能够自发的排尿(TWOCs均值为1.6±0.8),且热疗后不依赖导管的

默克的PD-1单抗Keytruda大大延长了部分晚期前列腺癌患者的生存期

根据默克公司第二阶段KEYNOTE-199研究的结果,默克公司(Merck)的重磅炸弹PD-1单抗Keytruda延长了一小部分晚期前列腺癌患者的生命。

Sci Rep:血清N-glycan是去势抵抗性前列腺的潜在生物标记

最近,有研究人员调查了血清N-glycan在去势抵抗性前列腺癌中的诊断和预后意义。研究人员回顾性的调查了287名良性前列腺增生(BPH)患者、289名新诊断前列腺癌(PC)患者、57名进行雄激素阻断治疗且无疾病恶化的PC患者(PC-ADT)和60名CRPC患者的糖印迹血清N-glycan结构分析情况,并比较了非CPRC患者(BPH、新诊断PC和PC-ADT)与CPRC患者的N-glycan情况。研

Baidu
map
Baidu
map
Baidu
map